GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » Other Operating Expense
中文

Alterity Therapeutics (Alterity Therapeutics) Other Operating Expense

: $0.00 Mil (TTM As of Sep. 2023)
View and export this data going back to 2002. Start your Free Trial

Alterity Therapeutics's Other Operating Expense for the three months ended in Sep. 2023 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Alterity Therapeutics's annual Other Operating Expense declined from Jun. 2021 ($-3.37 Mil) to Jun. 2022 ($-3.56 Mil) but then increased from Jun. 2022 ($-3.56 Mil) to Jun. 2023 ($-2.54 Mil).


Alterity Therapeutics Other Operating Expense Historical Data

The historical data trend for Alterity Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.33 0.02 -3.37 -3.56 -2.54

Alterity Therapeutics Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alterity Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alterity Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Alterity Therapeutics (Alterity Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Alterity Therapeutics (Alterity Therapeutics) Headlines

From GuruFocus

Appendix 4C � Q3 FY23 Quarterly Cash Flow Report

By sperokesalga sperokesalga 05-10-2023